{"entity":{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","aka":[],"tldr":"A phase 1/2 trial of Dual-target CAR-NK cell product in ovarian cancer, run by Beijing Biotech, now recruiting.","summary":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) is a phase 1/2 interventional study registered as NCT07480954 by Beijing Biotech, with 36 participants planned, started 2026-02-04 and due to reach its primary completion in 2027-02-17. Interventions recorded: Dual-target CAR-NK cell product and Lymphodepleting chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07480954","url":"https://clinicaltrials.gov/study/NCT07480954"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07480954","phase":"1/2","setting":"A Phase 1/2, Open-Label, Biomarker-Assigned Study of Dual-Targeting CAR-NK Cells Directed Against Mesothelin (MSLN), Folate Receptor Alpha (FRα/FOLR1), and/or MUC16 (CA125) in Patients With Recurrent or Refractory High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","sponsor":"Beijing Biotech","enrolled":36,"outcomes":[]},"route":"/trials/nct07480954/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}]}}